Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
7.61
+0.02 (0.26%)
At close: Nov 11, 2026, 4:00 PM EST
7.63
+0.02 (0.26%)
After-hours: Nov 11, 2026, 7:30 PM EST
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 7.00K CHF in the quarter ending September 30, 2026, a decrease of -97.12%. This brings the company's total for the last twelve months to 937.00K, up 18.31% year-over-year. In the year 2025, Oculis Holding AG had annual revenue of 1.20M with 74.78% growth. That makes Oculis Holding AG the 43,435th largest company in the world by revenue and 6,042nd in the United States.
Revenue (ttm)
937.00K CHF
Revenue Growth
+18.31%
P/S Ratio
418.31
Revenue / Employee
15,617 CHF
Employees
60
Market Cap
469.78M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | 993.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Gyre Therapeutics | 110.06M |
| Prothena Corporation | 52.74M |
| YD Bio | 1.24M |
| Shattuck Labs | 1.00M |
OCS News
- 8 hours ago - Oculis Holding AG Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 2 days ago - Oculis Holding AG Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 2 days ago - Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline - GlobeNewsWire
- 7 days ago - Oculis price target lowered to $40 from $45 at Guggenheim - TheFly
- 8 days ago - Oculis reports Q3 EPS (30c), consensus (39c) - TheFly
- 8 days ago - Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts - GlobeNewsWire
- 8 days ago - Oculis Holding AG Earnings release: Q3 2026 - Filings
- 9 days ago - Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation - GlobeNewsWire